Search Results

The Albumin Cobalt Binding Test (ACB® Test) is a quantitative in vitro diagnostic test used on human serum that detects Ischemia Modified Albumin (IMA™) by measuring the cobalt binding capacity of albumin in human serum. IMA is intended for use in conjunction with ECG and cardiac troponin as an aid to the short term risk stratification of patients presenting with chest pain suggestive of cardiac origin.

Thus, in patients with chest pain or equivalent symptoms suggestive of cardiac origin, with non-diagnostic ECG and normal troponin, a negative IMA can be used as an aid to rule out Acute Coronary Syndromes (ACS) in low risk patients.

Not Found

The provided text is a 510(k) premarket notification letter from the FDA regarding the "Albumin Cobalt Binding Test (ACB® Test)". It states the device's intended use and includes a required limitation in the labeling. However, it does not contain specific details about acceptance criteria, a study proving device performance against those criteria, sample sizes, expert qualifications, adjudication methods, or other details typically found in a clinical study report or a more comprehensive FDA submission summary.

Therefore, much of the requested information cannot be extracted from this document.

Here's what can be gleaned, along with the information that is explicitly missing:

1. Table of Acceptance Criteria and Reported Device Performance

Missing. The document primarily grants substantial equivalence based on a predicate device and outlines labeling requirements and limitations. It does not provide a table of acceptance criteria or specific performance metrics from a study (e.g., sensitivity, specificity, NPV, PPV) for the ACB® Test.

2. Sample Size Used for the Test Set and Data Provenance

Missing. No information on the sample size of a test set or the provenance (country of origin, retrospective/prospective) of data used to establish device performance is provided.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications

Missing. There is no mention of experts, how ground truth for a test set was established, or their qualifications.

4. Adjudication Method for the Test Set

Missing. No adjudication method is described.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

Missing. The document does not indicate that an MRMC study was performed or provide any effect size of human readers improving with or without AI assistance (which is not relevant for this type of in-vitro diagnostic device).

6. Standalone (Algorithm Only) Performance Study

Missing. While this is an "in vitro diagnostic product," the document doesn't detail any specific standalone performance study results.

7. Type of Ground Truth Used

Missing. The document states the device "detects Ischemia Modified Albumin (IMA™) by measuring the cobalt binding capacity of albumin in human serum" and is intended "as an aid to the short term risk stratification of patients presenting with chest pain suggestive of cardiac origin." It also mentions "normal troponin" and "non-diagnostic ECG" in its indications for use. However, it does not explain how the "ground truth" for ACS or risk stratification was established in any study to validate the device's performance.

8. Sample Size for the Training Set

Missing. No information on a training set sample size is provided.

9. How the Ground Truth for the Training Set Was Established

Missing. No information on how ground truth was established for a training set is provided.

In summary: This FDA letter focuses on regulatory approval and labeling limitations rather than a detailed scientific study summary. To obtain the requested information, one would typically need to review the full 510(k) submission, including the clinical and analytical performance studies, which are not part of this document.

Ask a specific question about this device